DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20221049

Threat of multidrug resistant bacterial pathogens in COVID-19 pandemic

Hari Prasad Nepal, Rama Paudel

Abstract


Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease first emerged in Wuhan, China in December 2019 and since then, has been spreading worldwide.1 On March 11, 2020, the World Health Organization (WHO) declared the disease a pandemic.2 This pandemic has been described as the greatest threat to global health since the Spanish Influenza pandemic in the 20th century.3


Keywords


COVID-19, WHO, SARS-CoV-2

Full Text:

PDF

References


Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new Coronavirus of probable bat origin. Nature. 2020;579:270-3.

World Health Organization (WHO). Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available at: https://www.who.int/director-general/speeches/detail /who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed on 12 March 2022.

Polly M, Almeida BLD, Lennon RP, Cortes MF, Costa SF, Guimaraes T. Impact of COVID-19 pandemic on the incidence of multidrug resistant bacterial infections in an acute care hospital in Brazil. AJIC. 2021;50(1):32-8.

Cennimo DJ. Coronavirus disease 2019 (COVID-19). Available at: https://emedicine.medscape.com /article/2500114-overview. Accessed on 12 March 2022.

World Health Organization (WHO). Coronavirus (COVID-19) dashboard. Available at: https://covid 19.who.int/. Accessed on 12 March 2022.

Anesi GL. COVID-19: epidemiology, clinical features, and prognosis of the critically ill adult. Available at: https://www.uptodate.com/content s/covid-19-epidemiology-clinical-features-and-prognosis-of-the-critically-ill-adult. Accessed on 12 March 2022.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet. 2020;395:507-13.

Guo M, Gao M, Gao J, Zhang T, Jin X, Fan J, et al. Identifying Risk Factors for secondary infection post-SARS-CoV-2 infection in patients with severe and critical COVID-19. Front Immunol. 2021;12:715023.

Aurilio C, Sansone P, Paladini A, Barbarisi M, Coppolino F, Pota V, et al. Multidrug resistence prevalence in COVID area. Life. 2021;11:601.

Pasero D, Cossu AP, Terragni P. Multi-drug resistance bacterial infections in critically ill patients admitted with COVID-19. Microorganisms. 2021;9:1773.

Grasselli G, Scaravilli V, Mangioni D, Scudeller L, Alagna L, Bartoletti M, et al. Hospital-acquired infections in critically ill patients with COVID-19. Chest. 2021;160:454.

Karruli A, Boccia F, Gabliardi M, Patauner F, Ursi MP, Sommese P, et al. Mutidrug-resistant infections and outcome of critically ill patients with Corona virus disease-2019: A single center experience. Microb Drug Resist. 2021;27(9):1167-75.

Costa RLD, Lamas CDC, Fernando L, Simvoulids N, Espanha CA, Pinto L, et al. Secondary infections in a cohort of patients with COVID-19 admitted to an intensive care unit: impact of Gram-negative bacterial resistance. Rev Inst Med Trop Sao Paulo. 2022;64:e6.

Langford BJ, So M, Raybardhan S, Leung V, Westwod D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID- 19: a living rapid review and meta-analysis. Clin Microbiol and Infect. 2020;26:1622-9.

World Health Organization (WHO). Clinical guidance for COVID- 19. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1. Accessed on 12 January 2022.